Alvotech (ALVO) Cost of Revenue (2022 - 2026)
Alvotech's (ALVO) quarterly Cost of Revenue came in at $52.2 million in Q2 2026, down 29.3% on a YoY basis from $73.8 million in Q2 2025, and up 13.26% quarter-over-quarter from $46.1 million in Q1 2026.
Analysis
Alvotech (ALVO) Cost of Revenue (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Cost of Revenue for 5 consecutive years, with $52.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cost of Revenue fell 29.3% year-over-year to $52.2 million; the trailing twelve-month figure through Jun 2026 stood at $272.6 million (down 25.2% YoY), and the FY2025 full-year result was $235.6 million, up 27.12% from the prior year.
- Cost of Revenue improved to $52.2 million in Q2 2026 per ALVO's latest filing, from $46.1 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $185.3 million in Q4 2024 and bottomed at -$46.3 million in Q2 2022.
- Historically, Cost of Revenue has averaged $67.8 million across 5 years, with a median of $58.1 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue surged 281.23% in 2023, then slumped 87.59% in 2024.
- Over 5 years, Cost of Revenue stood at $64.1 million in 2022, then surged by 150.96% to $160.9 million in 2023, then gained by 15.2% to $185.3 million in 2024, then decreased by 24.84% to $139.3 million in 2025, then plunged by 62.52% to $52.2 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $52.2 million, $46.1 million, and $139.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 1.99 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 2.30 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 455.94 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 461.69 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 753.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 100.16 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 52.20 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 90.43 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 721,000.00 |
| 10 | NutriBand | 72.57 Mn | 69.15 Mn | 181,874.00 | 255,640.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.20 Mn |
| Mar 31, 2026 | 46.09 Mn |
| Dec 31, 2025 | 139.27 Mn |
| Sep 30, 2025 | 35.01 Mn |
| Jun 30, 2025 | 73.83 Mn |
| Mar 31, 2025 | 65.45 Mn |
| Dec 31, 2024 | 185.31 Mn |
| Sep 30, 2024 | 39.81 Mn |
| Jun 30, 2024 | 45.21 Mn |
| Mar 31, 2024 | 19.96 Mn |
| Dec 31, 2023 | 160.86 Mn |
| Aug 31, 2023 | 67.91 Mn |
| Jun 30, 2023 | 28.81 Mn |
| Mar 20, 2023 | 160.86 Mn |
| Dec 31, 2022 | 64.10 Mn |
| Aug 31, 2022 | 17.81 Mn |
| Jun 30, 2022 | -46.28 Mn |
| Mar 20, 2022 | 64.10 Mn |